CME Harrington Relationships with Industry: Research, CME, Focus on Solutions Thomas Sullivan Mar 18, 2010 0 A recent lecture from Robert A. Harrington MD, FACC, focused on the "Relationships with Industry: Effects on the Academic…
ACCME Nissen Relationships with Industry: CME, Professional Societies and Red… Thomas Sullivan Mar 18, 2010 0 This week’s debate between Steven Nissen, MD Cleveland Clinic and Robert Harrington, MD Duke on Industry support of education…
Healthcare Reform Health Care Reform: Will the House Pass the Senate Bill Thomas Sullivan Mar 17, 2010 0 A recent memo from Ranking Republican of the House Rules Committee David Dreier (R-San Dimas, CA) asserted how “the Democratic…
Congress Senate Aging Committee Hearing: Rising Drug Prices Thomas Sullivan Mar 17, 2010 0 Today (Wednesday March 17, 2010), at 2:30 p.m., the Senate Special Committee on Aging will be holding a hearing in…
Medical Legal The Era of Big Pharma Fraud Cases May Be Ending Thomas Sullivan Mar 17, 2010 0 A recent interview with former US Attorney Michael K. Loucks noted that although “The Era of Big Pharma Fraud Cases Is Ending,”…
Media News Paper Targets Private Practice Physicians Speaking at Industry Events Thomas Sullivan Mar 16, 2010 0 As part of an ongoing series about how money and conflicts of interest affect medicine and patient care, the Milwaukee Journal…
Congress Congressional Hearing on Drug Safety: an Update from the FDA Thomas Sullivan Mar 15, 2010 0 Last week, The House Committee on Energy and Commerce, Subcommittee on Health held a hearing on “Drug Safety: An Update from the…
Healthcare Reform Health Care Reform: Democrat Congressman Calls for Starting from the… Thomas Sullivan Mar 15, 2010 0 This week Congress is in the final leg of passing health care reform, and politicians are gathering as many votes to save…
CME Continuing Education Reform: Are We Throwing the Baby Out With the… Thomas Sullivan Mar 12, 2010 0 Recent evaluations of professional societies and accredited continuing medical education (CME) providers have “further…
FDA FDA Educates Industry on Development of Orphan Drugs Thomas Sullivan Mar 11, 2010 0 In the complex and expensive world of research and development for drugs, there are therapies for conditions known as “orphan…